Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 134 (TMEM134) is a small, highly conserved transmembrane protein encoded by the TMEM134 gene, which is located on chromosome 11q13.2 in humans[1][3]. The protein has 195 amino acids and features two transmembrane domains as well as a domain of unknown function (DUF872)[1][3]. It is ubiquitously expressed in human tissues, with higher levels in the heart, breast, and prostate[1][4]. TMEM134 is predominantly localized to the endoplasmic reticulum and nuclear membrane, is predicted to be phosphorylated post-translationally, and interacts with proteins such as ELAVL1 and the EBV latent membrane protein 1 (LMP1)[1][3]. While its exact molecular function remains unknown, TMEM134 has been identified as a potential LMP1-binding partner and candidate oncogene in breast cancer models, suggesting possible roles in carcinogenesis or viral signaling pathways[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 134 (TMEM134).